FOLFIRINOX for the treatment of colorectal cancer: latest evidence from clinical trials

摘要

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide, with more than 200,000 deaths per year in Europe alone [1]. Over half of all patients with CRC will develop metastatic disease, with a quarter having distant metastatic lesions at diagnosis [2]. In the setting of unresectable metastatic CRC the best outcome is achieved in patients receiving fluoropyrimidines oxali-platin and irinotecan in their course of disease [3]. Over the last decade, several combinations of these three drugs significantly increased response rate (RR) and prolonged overall survival (OS) with a RR of 40-50% and a median OS of up to 20 months [4].